Ziko Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 08-07-2024
- Paid Up Capital ₹ 1.50 M
as on 08-07-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 44.58%
(FY 2023)
- Ebitda 53.08%
(FY 2023)
- Net Worth -2.70%
(FY 2023)
- Total Assets -0.63%
(FY 2023)
About Ziko Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Faisal Khan and Adil Khan serve as directors at the Company.
- CIN/LLPIN
U24304UP2017PTC093921
- Company No.
093921
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ziko Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Faisal Khan  | Director | 07-Jun-2017 | Current |
| Adil Khan | Director | 07-Jun-2017 | Current |
Financial Performance of Ziko Pharmaceuticals.
Ziko Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 44.58% increase in profit. The company's net worth dipped by a decrease of 2.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ziko Pharmaceuticals?
In 2023, Ziko Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Urbandoor Lifecare Private LimitedActive 6 years 5 monthsFaisal Khan and Adil Khan are mutual person
Urbandoor Infratech Private LimitedActive 10 years 1 monthFaisal Khan and Adil Khan are mutual person
Haxtax Insurance Broking Private LimitedActive 3 years 8 monthsFaisal Khan and Adil Khan are mutual person
Haxtax Management Consultancy Private LimitedActive 7 years 4 monthsFaisal Khan and Adil Khan are mutual person
Urbandoor Resorts Private LimitedActive 7 years 7 monthsFaisal Khan and Adil Khan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ziko Pharmaceuticals?
Unlock and access historical data on people associated with Ziko Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ziko Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ziko Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
